Loading…
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2024
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2024 | $0M | $-16M | $-16M | $-7M | -623.1% | - | - |
| 2023 | $0M | $-9M | $-9M | $-6M | -132.7% | - | - |
| 2022 | $0M | $-8M | $-8M | $-6M | -59.2% | - | - |
| 2021 | $0M | $-5M | $-5M | $-4M | -17.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 4.60 | 8.04 | 9.33 | 16.01 |
| Operating Income | -4.60 | -8.04 | -9.33 | -16.01 |
| EBITDA | -4.59 | -8.04 | -9.32 | -16.01 |
| EBIT | -4.60 | -8.04 | -9.33 | -16.01 |
| Pretax Income | -4.57 | -7.83 | -8.89 | -15.79 |
| Net Income | -4.57 | -7.83 | -8.89 | -15.79 |
| Net Income Common Stockholders | -4.57 | -7.83 | -8.89 | -15.79 |
| Total Expenses | 4.60 | 8.04 | 9.33 | 16.01 |
| Interest Income | 0.03 | 0.22 | 0.44 | 0.22 |
| Research And Development | 3.56 | 6.48 | 7.70 | 12.95 |
| Selling General And Administration | 1.04 | 1.56 | 1.63 | 3.06 |
| Normalized EBITDA | -4.59 | -8.04 | -9.32 | -16.01 |
| Normalized Income | -4.57 | -7.83 | -8.89 | -15.79 |
| Basic EPS | -0.35 | -0.61 | -0.69 | -1.21 |
| Diluted EPS | -0.35 | -0.61 | -0.69 | -1.21 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -4.57 | -7.83 | -8.89 | -15.79 |
| Reconciled Depreciation | 0 | 0 | 0 | 0 |
| Net Interest Income | 0.03 | 0.22 | 0.44 | 0.22 |
| Net Income From Continuing And Discontinued Operation | -4.57 | -7.83 | -8.89 | -15.79 |
| Total Operating Income As Reported | -4.60 | -8.04 | -9.33 | -16.01 |
| Diluted Average Shares | 12.94 | 12.91 | 12.85 | 13.01 |
| Basic Average Shares | 12.94 | 12.91 | 12.85 | 13.01 |
| Diluted NI Availto Com Stockholders | -4.57 | -7.83 | -8.89 | -15.79 |
| Net Income Including Noncontrolling Interests | -4.57 | -7.83 | -8.89 | -15.79 |
| Net Income Continuous Operations | -4.57 | -7.83 | -8.89 | -15.79 |
| Net Non Operating Interest Income Expense | 0.03 | 0.22 | 0.44 | 0.22 |
| Interest Income Non Operating | 0.03 | 0.22 | 0.44 | 0.22 |
| General And Administrative Expense | 1.04 | 1.56 | 1.63 | 3.06 |
| Other Gand A | 1.04 | 1.56 | 1.63 | 3.06 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Greenwich LifeSciences, Inc.this co. | GLSI | $299M | - | 136.71 | -623.1% | -15.09 |
| ClearPoint Neuro, Inc. | CLPT | $310M | - | 10.84 | -91.1% | -14.85 |
| Anavex Life Sciences Corp. | AVXL | $302M | - | 2.39 | -48.9% | - |
| Compass Therapeutics, Inc. | CMPX | $301M | - | 1.51 | -33.8% | -1.40 |
| Rezolute, Inc. | RZLT | $299M |
| - |
| 2.53 |
| -45.9% |
| -1.89 |
| Organogenesis Holdings Inc. | ORGO | $296M | 15.33 | 0.97 | 8.5% | 5.55 |
| Protara Therapeutics, Inc. | TARA | $285M | - | 1.41 | -29.2% | -1.99 |
| LENZ Therapeutics, Inc. | LENZ | $284M | - | 1.00 | -28.9% | 0.09 |
| Simulations Plus, Inc. | SLP | $283M | - | 2.11 | -51.9% | 17.29 |
| Peer Median | - | 15.33 | 1.81 | -39.8% | -1.40 | |